Literature DB >> 11196197

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

P Pourquier1, J L Waltman, Y Urasaki, N A Loktionova, A E Pegg, J L Nitiss, Y Pommier.   

Abstract

Alkylating agents such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) are known to covalently link alkyl groups at the position 6 of guanines (O6MG) in DNA. O6-alkylguanine-DNA alkyltransferase (AGT) specifically removes the methyl group of the O6MG. Using purified human topoisomerase I (Top1), we found an 8-10-fold enhancement of Top1 cleavage complexes when O6MG is incorporated in oligonucleotides at the +1 position relative to a unique Top1 cleavage site. Top1 poisoning by O6MG is attributable to a decrease of the Top1-mediated DNA religation as well as an increase in the enzyme cleavage step. Increased cleavage is probably linked to a change in the hydrogen bonding pattern, such as in the case of the 8-oxoguanine, whereas inhibition of religation could be attributed to altered base pairing, such as abasic sites or base mismatches, because incorporation of a 6-thioguanine did not affect Top1 activity. Top1-DNA covalent complexes are also induced in MNNG-treated CHO cells constitutively lacking the AGT enzyme. Conversely, no increase could be detected in CHO cells transfected with the wild-type human AGT. Moreover, we show that yeasts overexpressing the human Top1 are more sensitive to MNNG, whereas knock-out Top1 strain cells display some resistance to the drug. Altogether, these results suggest a role for Top1 poisoning by alkylated bases in the antiproliferative activity of alkylating agents as well as in the DNA lesions resulting from endogenous and carcinogenic DNA modifications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196197

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro.

Authors:  Holger Stephan; Frank Grosse; Kent Søe
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

2.  p53 stimulates human topoisomerase I activity by modulating its DNA binding.

Authors:  Kent Søe; Frank Grosse
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

Review 3.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

Review 4.  Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).

Authors:  Yves Pommier; Shar-yin N Huang; Rui Gao; Benu Brata Das; Junko Murai; Christophe Marchand
Journal:  DNA Repair (Amst)       Date:  2014-05-22

5.  Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

Authors:  Lars M Wagner; Judith G Villablanca; Clinton F Stewart; Kristine R Crews; Susan Groshen; C Patrick Reynolds; Julie R Park; John M Maris; Randall A Hawkins; Heike E Daldrup-Link; Hollie A Jackson; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

6.  A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.

Authors:  Darren Hargrave; Birgit Geoerger; Didier Frappaz; Torsten Pietsch; Lyle Gesner; Laura Cisar; Aurora Breazna; Andrew Dorman; Ofelia Cruz-Martinez; Jose Luis Fuster; Xavier Rialland; Céline Icher; Pierre Leblond; David Ashley; Giorgio Perilongo; Martin Elliott; Martin English; Niels Clausen; Jacques Grill
Journal:  J Neurooncol       Date:  2013-03-04       Impact factor: 4.130

7.  Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

Authors:  David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sridharan Gururangan; James Vredenburgh; John H Sampson; James M Provenzale; Amy Walker; Michael Badruddoja; Sandra Tourt-Uhlig; James E Herndon; Jeannette M Dowell; Mary Lou Affronti; Susanne Jackson; Deborah Allen; Karen Ziegler; Steven Silverman; Cindy Bohlin; Allan H Friedman; Darell D Bigner; Henry S Friedman
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

8.  Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman
Journal:  J Neurooncol       Date:  2009-06-17       Impact factor: 4.130

9.  Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

10.  Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

Authors:  M R Litzow; P P Peethambaram; S L Safgren; G L Keeney; S M Ansell; A Dispenzieri; M A Elliott; D A Gastineau; M A Gertz; D J Inwards; M Q Lacy; I N M Micallef; L F Porrata; W L Lingle; L C Hartmann; M H Frost; B A Barrette; H J Long; V J Suman; J M Reid; M M Ames; S H Kaufmann
Journal:  Bone Marrow Transplant       Date:  2009-08-03       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.